NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ
Yıl: 2020 Cilt: 20 Sayı: 1 Sayfa Aralığı: 224 - 233 Metin Dili: Türkçe DOI: 10.5505/amj.2020.41961 İndeks Tarihi: 29-11-2020
NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ
Öz: Amaç: Bu çalışmada, Nörofibromatozis tip 1 (NF1) tanılı olgularımızın demografik, klinik, laboratuvarbulgularını ve tedavilerini geriye dönük olarak değerlendirmek ve Amerika Birleşik Devletleri Ulusal SağlıkEnstitüsü (NIH) tanı kriterlerine göre hastaları tanımlayarak literatür ile karşılaştırmak amaçlanmıştır.Materyal ve Metot: Ocak 2015-Ocak 2019 tarihleri arasında merkezimize başvuran ve NF1 tanısı ile izlenen18 olgunun klinik ve radyolojik bulguları geriye dönük olarak incelendi.Bulgular: Hastaların ilk başvurudaki ortanca yaşı 8 yıl (1-17 yıl) idi. Başvuru yakınmaları 16 olguda cilttekilekeler, 1 olguda karın ağrısı, 1 olguda çenede şişlik idi. Sütlü kahve lekeleri olguların tümünde,aksiller/inguinal çillenme 9’unda (%50), lisch nodülü 13’ünde (%72,22), kemik lezyonları 3’ünde (%16,66) [2olguda skolyoz ve 1 olguda lordoz], nörofibrom 1’inde (%5,55), pleksiform nörofibrom 1’inde (%5,55) görüldü.Boy kısalığı 3 (%16,66) olguda tespit edildi. Bunlardan biri büyüme hormonu eksikliği olarak değerlendirildi.Okula devam eden 10 hastadan, 5'inin (%27,77) ders başarısı kötüydü. Bu olgulardan 2’si(%11,11) dikkateksikliği hiperaktivite sendromu tanısı ile izlenmekte idi. Beyin manyetik rezonans görüntüleme (MRG)’de 6(%33,33) olguda hamartomatöz lezyon, 1(%5,55) olguda optik gliom saptandı.Sonuç: Araştırmamızda, hasta grubunun klinik ve radyolojik bulgularının literatür ile uyumlu olduğunusaptadık. Mortalite oranı kansere yatkınlık ve vaskülopatiler nedeni ile yüksek olan bu hastalıkta, gelişebilecekkomplikasyonların erken saptanması, izlemi ve tedavisi açısından, hastaların yaşam boyu multidisipliner takibigerekmektedir.
Anahtar Kelime: CLINICAL AND RADIOLOGICAL FEATURES OF NEUROFIBROMATOSIS TYPE 1: SINGLE CENTER'S EXPERIENCE
Öz: Objectives: The aim of this study was to review our institutional experience with the clinical characteristics, imaging findings, and therapies in Neurofibromatosis type 1 (NF1) and defining the patients according to the USA- National Institute of Health (NIH) diagnostic criteria and comparing them with the literature. Materials and Methods: Clinical and imaging findings of 18 children with NF1, treated at our hospital from January 2015 to January 2019, were retrospectively evaluated. Results: The study group included 18 children diagnosed with NF1 according to NIH diagnostic criteria. Thirteen patients were female and 5 were male. The median age at admission was 8 years (1-17 years). The presenting symptoms were cafe-au-laits spots in 16 cases, abdominal pain in 1 case and jaw swelling in 1 case. All patients had cafe-au-lait spots, 9 (50%) axillary / inguinal freckles, 13 (72.22%) lisch nodules, 3 (16.66%) bone lesions, 1 (5.55%) neurofibromas and 1 (5.55%) plexiform neurofibromas. Short stature was detected in 3 (16.66%) cases. One of them was evaluated as growth hormone deficiency. Of the 10 patients attending school, 5 (27.77%) had poor school performance. Two of these cases (11.11%) were being diagnosed with ADHD. On magnetic resonance imaging, 6 (33.33%) cases had hamartomatous lesion and 1 (5.55%) case optic glioma. Conclusion: We found that the clinical and radiological findings of the patient group were consistent with the literature. Multidisciplinary follow-up of patients throughout the lifetime is necessary for the early detection, follow-up and treatment of complications.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Plon SE, Malkin D. Childhood cancer and heredity. In: Pizzo PA, Poplack DG (eds). Principles and practice of pediatric oncology. 7th ed., Philadelphia: Wolters Kluwer; 2016:22-23.
- 2. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet. 2007;44(2):81-8.
- 3. Hirbe AC, Gutmann DH. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol. 2014;13(8):834-43.
- 4. Dunning-Davies BM, Parker AP. Annual review of children with neurofibromatosis type 1. Arch Dis Child Educ Pract Ed. 2016;101(2):102-11.
- 5. Kose G, Ozaydın E, Hasancebi B, Guven A. Neurofibromatosis type 1: clinical evaluation of 44 patients. Türkiye Klinikleri J Pediatr. 2008;17:89-95.
- 6. Çarman K, Yarar C, Ekici A, et al. Nörofibromatozis Tip 1: 49 Olgunun Değerlendirilmesi. Haydarpaşa Numune Med J. 2017;57:157-60.
- 7. Kim MJ, Cheon CK. Neurofibromatosis type 1: a single center's experience in Korea. Korean J Pediatr. 2014;57:410-5.
- 8. Cnossen MH, de Goede-Bolder A, van den Broek KM, et al. A prospective 10 year follow up study of patients with neurofibromatosis type 1. Archives of disease in childhood. 1998;78(5):408-12.
- 9. Shah K. The Diagnostic and Clinical Significance of Café-au-lait Macules. Pediatr Clin N Am. 2010; 57(5):1131-53.
- 10. Messiaen L1, Yao S, Brems H, et al. Clinical and mutational spectrum of neurofibromatosis type 1-like syndrome. JAMA. 2009;302:2111-8.
- 11. Wimmer K, Rosenbaum T, Messiaen L. Connections between constitutional mismatch repair deficiency syndrome and neurofibromatosis type 1. Clinical genetics. 2017;91(4):507-19.
- 12. Matsui I, Tanimura M, Kobayashi N, Sawada T, Nagahara N, Akatsuka J. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993;72(9):2746-54.
- 13. Clemens RK, Lillis AP, Perez-Rossello J, et al. Misdiagnosis of plexiform neurofibroma as venous malformation in pediatric patients. International angiology : a journal of the International Union of Angiology. 2016;35(6):613-21.
- 14. Drappier JC, Khosrotehrani K, Zeller J, Revuz J, Wolkenstein P. Medical management of neurofibromatosis 1: a cross-sectional study of 383 patients. Journal of the American Academy of Dermatology. 2003;49(3):440-4.
- 15. Carmi D, Shohat M, Metzker A, Dickerman Z. Growth, puberty, and endocrine functions in patients with sporadic or familial neurofibromatosis type 1: a longitudinal study. Pediatrics. 1999;103(6 Pt 1):1257-62.
- 16. Vassilopoulou-Sellin R, Klein MJ, Slopis JK. Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions. Pediatr Neurol. 2000;22(5):355-8.
- 17. Barton B, North K. Social skills of children with neurofibromatosis type 1. Dev Med Child Neurol. 2004;46(8):553-63.
- 18. Pride NA, Payne JM, North KN. The impact of ADHD on the cognitive and academic functioning of children with NF1. Dev Neuropsychol. 2012;37(7):590-600.
- 19. Menor F, Marti-Bonmati L, Arana E, Poyatos C, Cortina H. Neurofibromatosis type 1 in children: MR imaging and follow-up studies of central nervous system findings. Eur J Radiol. 1998;26(2):121-31.
- 20. Kehrer-Sawatzki H, Mautner VF, Cooper DN. Emerging genotype-phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017;136(4):349-76.
| APA | İNCESOY ÖZDEMİR S, Citak Kurt A, özlü s (2020). NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. , 224 - 233. 10.5505/amj.2020.41961 |
| Chicago | İNCESOY ÖZDEMİR SONAY,Citak Kurt Aysegul Nese,özlü sare gülfem NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. (2020): 224 - 233. 10.5505/amj.2020.41961 |
| MLA | İNCESOY ÖZDEMİR SONAY,Citak Kurt Aysegul Nese,özlü sare gülfem NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. , 2020, ss.224 - 233. 10.5505/amj.2020.41961 |
| AMA | İNCESOY ÖZDEMİR S,Citak Kurt A,özlü s NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. . 2020; 224 - 233. 10.5505/amj.2020.41961 |
| Vancouver | İNCESOY ÖZDEMİR S,Citak Kurt A,özlü s NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. . 2020; 224 - 233. 10.5505/amj.2020.41961 |
| IEEE | İNCESOY ÖZDEMİR S,Citak Kurt A,özlü s "NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ." , ss.224 - 233, 2020. 10.5505/amj.2020.41961 |
| ISNAD | İNCESOY ÖZDEMİR, SONAY vd. "NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ". (2020), 224-233. https://doi.org/10.5505/amj.2020.41961 |
| APA | İNCESOY ÖZDEMİR S, Citak Kurt A, özlü s (2020). NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. Ankara Medical Journal, 20(1), 224 - 233. 10.5505/amj.2020.41961 |
| Chicago | İNCESOY ÖZDEMİR SONAY,Citak Kurt Aysegul Nese,özlü sare gülfem NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. Ankara Medical Journal 20, no.1 (2020): 224 - 233. 10.5505/amj.2020.41961 |
| MLA | İNCESOY ÖZDEMİR SONAY,Citak Kurt Aysegul Nese,özlü sare gülfem NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. Ankara Medical Journal, vol.20, no.1, 2020, ss.224 - 233. 10.5505/amj.2020.41961 |
| AMA | İNCESOY ÖZDEMİR S,Citak Kurt A,özlü s NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. Ankara Medical Journal. 2020; 20(1): 224 - 233. 10.5505/amj.2020.41961 |
| Vancouver | İNCESOY ÖZDEMİR S,Citak Kurt A,özlü s NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ. Ankara Medical Journal. 2020; 20(1): 224 - 233. 10.5505/amj.2020.41961 |
| IEEE | İNCESOY ÖZDEMİR S,Citak Kurt A,özlü s "NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ." Ankara Medical Journal, 20, ss.224 - 233, 2020. 10.5505/amj.2020.41961 |
| ISNAD | İNCESOY ÖZDEMİR, SONAY vd. "NÖROFİBROMATOZİS TİP 1’DE KLİNİK VE RADYOLOJİK BULGULAR: TEK MERKEZ DENEYİMİ". Ankara Medical Journal 20/1 (2020), 224-233. https://doi.org/10.5505/amj.2020.41961 |
